QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer

Ovarian cancer is one of the most common gynecologic malignancies, with considerable histologic heterogeneity; more than 90 % of cases are epithelial ovarian cancers. Because no reliable tools exist for early detection, approximately 70 % of patients are diagnosed at an advanced stage and have poor prognosis, and \>70 % experience relapse within 3 years of initial treatment. The standard first-line strategy combines cytoreductive surgery, platinum-based chemotherapy, and maintenance with PARP inhibitors. Management of recurrent disease remains one of the most challenging problems in clinical o

Trial Details

NCT ID
NCT07286240
Phase
PHASE2
Sponsor
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Status
RECRUITING
Cancer Type
Clear Cell Ovarian Cancer
Interventions
  • QL1706 plus chemotherapy and anlotinib regimen
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Capable of understanding and voluntarily signing the written Informed Consent Form (ICF); the ICF must be signed before any study-specific procedur…
  • Female, aged 18-70 years at the time of ICF signature. 3.Eastern Cooperative Oncology Group (ECOG) performance status 0-1. 4.Life expectancy ≥ 3 mo…
  • Platinum-sensitive relapse (recurrence ≥ 6 months after completion of the last platinum-based therapy).
  • Platinum-resistant relapse (recurrence \< 6 months after completion of the last platinum-based therapy or progression while on PARP-inhibitor maint…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Clear Cell Ovarian Cancer Trials on Trialify →